Dr. Tulika Ranjan is a prominent neuro-oncologist who joined the Allegheny Health Network (AHN) Cancer Institute as director of its Adult Neuro-Oncology Program in 2015. She also serves as disease site chair for AHN Cancer Institute Neurologic Oncology. Dr. Ranjan treats adult primary brain and spinal cord tumor – glioblastoma multiforme (GBM), anaplastic astrocytomas, oligodendrogliomas and other benign and malignant gliomas, schwannoma, ependymomas, adult edulloblastoma, and meningioma, as well as CNS lymphoma, paraneoplastic syndrome, and brain metastases. She has a comprehensive neuro-oncology multidisciplinary team with advance management modalities like Laser Interstitial thermal therapy, Cancer Stem Cell Chemo-sensitivity Testing, Optune, and Gamma Knife. Dr. Ranjan came to AHN from Duke University Preston Robert Tisch Brain Tumor Center in North Carolina, where she served on a collaborative clinical research team that developed a promising new therapy using the polio virus to treat GBM. Her research focuses on newer therapies for glioblastoma and precision medicine. She leads the recurrent national GBM clinical trial, “Standard Chemotherapy Versus Chemotherapy Chosen by Cancer Stem Cell Chemo Sensitivity Testing in the Management of Patients with Recurrent GBM.” Dr. Ranjan completed her Neuro-Oncology fellowship at Memorial Sloan Kettering Cancer Center in New York. She is board- certified in Neuro-Oncology and Neurology.